Latest period
−$44.36M
YoY change
+5.6%
5Y CAGR
—
Peak year (2020)
$70.07M
Latest annual
−$138.89M
Operating Cash Flow history chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: −$138.89M
Operating Cash Flow growth chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: +5.6%
Operating Cash Flow history table for Tango Therapeutics (TNGX) from 2019 to 2025
| 2025 | −$138.89M | +5.6% | −$7.38M | ||
| 2024 | −$131.50M | +11.5% | −$13.52M | ||
| 2023 | −$117.98M | +8.2% | −$8.90M | ||
| 2022 | −$109.08M | +83.2% | −$49.55M | ||
| 2021 | −$59.53M | -184.9% | −$129.60M | ||
| 2020 | $70.07M | -382.5% | +$94.88M | ||
| 2019 | −$24.80M | — | — |
- 2025−$138.89M+5.6%
- 2024−$131.50M+11.5%
- 2023−$117.98M+8.2%
- 2022−$109.08M+83.2%
- 2021−$59.53M-184.9%
- 2020$70.07M-382.5%
- 2019−$24.80M—
Operating Cash Flow values are taken from Tango Therapeutics's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Cash Flow at Tango Therapeutics (TNGX)
Operating Cash Flow for Tango Therapeutics (TNGX): headline value −$44.36M · YoY +5.6%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual operating cash flow for Tango Therapeutics (TNGX) came in at −$138.89M – grew 5.6% year-over-year.
Tango Therapeutics operating cash flow plunged from $70.07M in 2020 to −$138.89M in 2025, a 298.2% drawdown.
The highest annual operating cash flow of $70.07M was reported in 2020. The lowest in the available history was −$138.89M in 2025.
Tango Therapeutics Operating Cash Flow by Year
Tango Therapeutics Operating Cash Flow 2025: −$138.89M
In 2025, Tango Therapeutics reported operating cash flow of −$138.89M, grew 5.6% from 2024. This figure represents the lowest annual value in the available history.
Tango Therapeutics Operating Cash Flow 2024: −$131.50M
Tango Therapeutics operating cash flow in 2024 was −$131.50M, grew 11.5% from 2023.
Tango Therapeutics Operating Cash Flow 2023: −$117.98M
2023's operating cash flow for Tango Therapeutics came in at −$117.98M, grew 8.2% from 2022.
Tango Therapeutics Operating Cash Flow 2022: −$109.08M
Tango Therapeutics posted operating cash flow of −$109.08M in 2022, surged 83.2% from 2021.
Tango Therapeutics Operating Cash Flow 2021: −$59.53M
Tango Therapeutics operating cash flow in 2021 was −$59.53M.
See more financial history for Tango Therapeutics (TNGX).
Sector peers by Operating Cash Flow
Healthcare peers of Tango Therapeutics (TNGX), ranked by their latest operating cash flow
| $24.53B | |
| $19.70B | |
| $19.03B | |
| $18.56B | |
| $16.81B | |
| $16.47B | |
| $14.57B | |
| $9.96B |
- $24.53B
- $19.70B
- $19.03B
- $18.56B
- $16.81B
- $16.47B
- $14.57B
- $9.96B
Frequently asked questions
Tango Therapeutics (TNGX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation